Pharmafile Logo

COUCH Medcomms

Consumer health specialist joins Research Partnership Inc

Global healthcare market research consultancy Research Partnership has appointed Jennifer Stewart as a Director in their US offices in Philadelphia.

Inizio

White paper helps industry navigate new NHS roadmap

New report shows how pharma can support the NHS in the Covid-19 recovery era

Wilmington Healthcare

- PMLiVE

COVID-19 vaccine ‘unlikely’ to be available this year, says UK’s chief medical officer

Chris Whitty warns that there is no certainty that an effective vaccine will be available before winter 2021

- PMLiVE

FDA grants emergency approval for blood plasma treatments for COVID-19

Emergency approval granted despite concerns from top US health officials

- PMLiVE

Audentes’ rare disease gene therapy programme delayed after third patient death

Third patient death caused by gastrointestinal bleeding

- PMLiVE

Vertex’s triple combination CF therapy to become available on the NHS

The drug will immediately become available to thousands of cystic fibrosis patients

- PMLiVE

Meet OPEN Health and Pharmerit Experts at the World Orphan Drug Virtual USA Congress

Join OPEN Health and Pharmerit – an OPEN Health Company at the World Orphan Drug Virtual Congress from August 24-27, 2020, as we present:Advanced Therapies Commercial: Tuesday, August 25Succeeding with Star Wars...

OPEN Health

- PMLiVE

We need to keep learning to keep innovating

How embracing experimentation and making space for learning can fuel creativity

- PMLiVE

Keytruda improves survival in first-line oesophageal cancer

Topline data demonstrates promising efficacy in the first-line setting

- PMLiVE

Janssen scores another expansion for new Darzalex combination in the US

Myeloma med approved in combination with Amgen's Kyprolis

- PMLiVE

Novartis wins FDA approval for relapsing MS drug Kesimpta

Swiss pharma company is expecting EU approval for treatment next year

- PMLiVE

Pifzer, BioNTech eye October approval for mRNA-based COVID-19 vaccine

Companies share additional phase 1 safety and tolerability data

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links